You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Madison, Wisconsin 53792

  • Pain


RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS.

Study summary:

OBJECTIVES: - Investigate the effectiveness of flecainide in the management of neuropathic pain. OUTLINE: Patients are given a brief pain inventory (BPI) form to assess their pain upon enrollment in the study. Following a 7 day stabilization period, flecainide is administered. One capsule of flecainide is given twice a day on days 8-10, two capsules are given twice a day on days 11-14 and three capsules are given twice a day on days 15-21. BPI forms are completed on days 8, 15 and 22 to assess neuropathic pain. PROJECTED ACCRUAL: A total of 7-20 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Chronic neuropathic pain with diagnosis of cancer or AIDS PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - SGOT no greater than 2 times upper limit of normal (ULN) Renal: - Creatinine no greater than 2 times ULN Cardiovascular: - No clinical history of infarction or angina - No advanced heart failure - No sick sinus syndrome, intraventricular conduction disease, second or third degree AV block or arrhythmias requiring treatment (exception may be granted by cardiac consult) - No focal wall motion abnormalities - Ejection fraction at least 40% - Systolic blood pressure at least 90 mm Hg Other: - Must be able to take oral medication - No known allergy or adverse reaction to flecainide, mexilitene or any other type I antiarrhythmic drug - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 2 weeks since prior chemotherapy that may cause neuropathy Endocrine therapy: - At least 2 weeks since prior corticosteroids Radiotherapy: - Not specified Surgery: - Not specified Other: - No tricyclic antidepressant treatment within past 2 weeks - No concurrent use of flecainide, mexiletene or any other type I antiarrhythmic drug

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Flecainide in Treating Patients With Chronic Neuropathic Pain

Official Title:

Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial

Overall Status:


Study Phase:

Phase 2



Minimum Age:

19 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Eastern Cooperative Oncology Group

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Primary Purpose: Supportive Care

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Charles F. Von Gunten, MD, PhD
Study Chair
Robert H. Lurie Cancer Center

Study Dates

Start Date:February 1998
Primary Completion Date:April 2006
Primary Completion Type:Actual
Verification Date:January 2010
Last Changed Date:January 26, 2010
First Received Date:November 1, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:flecainide acetate

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Eastern Cooperative Oncology Group
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Results Reference
Citation:von Gunten CF, Eappen S, Cleary JF, Taylor SG 4th, Moots P, Regevik N, Cleeland C, Cella D. Flecainide for the treatment of chronic neuropathic pain: a Phase II trial. Palliat Med. 2007 Dec;21(8):667-72.

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.